ScreenPoint Medical's Transpara® Breast AI Selected for $16M PRISM Randomized Controlled Trial in USA

NEW YORK and NIJMEGEN, Netherlands, Sept. 23, 2025 /PRNewswire/ -- ScreenPoint Medical today announced that its Transpara^® breast imaging AI solution has been selected as the technology of choice for the PRISM (Pragmatic Randomized Trial of Artificial Intelligence for Screening Mammography) Trial, a landmark randomized controlled trial funded by the Patient-Centered Outcomes Research Institute (PCORI). Fueled by a $16 million award, this is the first large-scale trial in the United States to rigorously evaluate the role of artificial intelligence (AI) in breast cancer screening.

Led by UCLA and UC Davis, the PRISM Trial will study whether AI support can help radiologists detect breast cancer earlier, improve mammography accuracy, and reduce unnecessary patient callbacks. Furthermore, the trial will include focus groups and surveys to capture the patient experience and assess the perception of artificial intelligence for both clinicians and patients.

The study will involve hundreds of thousands of mammograms interpreted at leading academic medical centers including UCLA, UC Davis, UC San Diego, Boston Medical Center, University of Miami, University of Washington/Fred Hutchinson Cancer Center, and University of Wisconsin–Madison. ScreenPoint Medical's Transpara Detection software will be used as part of the study protocol with clinical workflow integration provided by the Aidoc aiOS platform.

"This landmark trial attests to three pillars: the pioneering vision of the researchers involved, PCORI's forward-thinking perspective on technology, and the potential of AI to help radiologists shape a healthier future," said Pieter Kroese, Chief Executive Officer of ScreenPoint Medical.  "We are honored that Transpara was selected for the PRISM Trial. We are equally proud to support academic medical centers and breast imaging facilities in advancing earlier breast cancer detection as well as more patient-centered and personalized systems of care."

Backed by a proven, prospective, and persuasive track record of breast imaging AI research, ScreenPoint Medical's Transpara Breast AI is used across imaging service lines, academic institutions, and screening programs around the globe, with over 10 million mammograms analyzed to date. Transpara is the technology trusted by radiologists and patients alike to enhance accuracy, improve consistency, and maximize efficiency while ensuring physicians remain central to every decision.

About ScreenPoint Medical
In the fight against breast cancer, every image is an opportunity: to unlock insight, to uncover risk, to embody health, to empower life. We build AI-powered technology for every step of the breast imaging continuum, improving consistency, reducing uncertainty, enhancing patient experience, and translating opportunity into tangible outcomes.

Proven through research, driven by innovation, and tailor-made for those seeking to lead in breast health, ScreenPoint's Transpara Breast AI is trusted by radiologists and women across the globe. We are Breast AI.

Learn more at: https://screenpoint-medical.com

Logo - https://mma.prnewswire.com/media/1582198/ScreenPoint_Medical_Logo.jpg

SOURCE ScreenPoint Medical